These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8150754)

  • 21. Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis.
    Barbhaiya RH; Knupp CA; Pfeffer M; Zaccardelli D; Dukes GM; Mattern W; Pittman KA; Hak LJ
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1387-91. PubMed ID: 1510432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety, tolerance, and pharmacokinetics of cefepime administered intramuscularly to healthy subjects.
    Barbhaiya RH; Knupp CA; Tenney J; Martin RR; Weidler DJ; Pittman KA
    J Clin Pharmacol; 1990 Oct; 30(10):900-10. PubMed ID: 2229450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of cefepime in patients with respiratory tract infections.
    Kovarik JM; ter Maaten JC; Rademaker CM; Deenstra M; Hoepelman IM; Hart HC; Matzke GR; Verhoef J
    Antimicrob Agents Chemother; 1990 Oct; 34(10):1885-8. PubMed ID: 2291655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cefepime. Pharmacokinetics and clinical response in patients with cystic fibrosis.
    Arguedas AG; Stutman HR; Zaleska M; Knupp CA; Marks MI; Nussbaum E
    Am J Dis Child; 1992 Jul; 146(7):797-802. PubMed ID: 1496945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens.
    Rhodes NJ; Grove ME; Kiel PJ; O'Donnell JN; Whited LK; Rose DT; Jones DR; Scheetz MH
    Int J Antimicrob Agents; 2017 Sep; 50(3):482-486. PubMed ID: 28668694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers.
    Fornasini G; Monti N; Brogin G; Gallina M; Eandi M; Persiani S; Bani M; Della Pepa C; Zara G; Strolin Benedetti M
    Chirality; 1997; 9(3):297-302. PubMed ID: 9176996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia.
    Aitken SL; Altshuler J; Guervil DJ; Hirsch EB; Ostrosky-Zeichner LL; Ericsson CD; Tam VH
    Int J Antimicrob Agents; 2015 May; 45(5):541-4. PubMed ID: 25665726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing.
    Lipman J; Wallis SC; Rickard CM; Fraenkel D
    Intensive Care Med; 2001 Feb; 27(2):363-70. PubMed ID: 11396280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple-dose pharmacokinetics of ceftibuten after oral administration to healthy volunteers.
    Bressolle F; Galtier M; Kinowski JM; Goncalves F; Edno L; Panis R; Gomeni R
    J Pharm Sci; 1994 Sep; 83(9):1236-40. PubMed ID: 7830237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects.
    Rodvold KA; Gotfried MH; Chugh R; Gupta M; Patel A; Chavan R; Yeole R; Friedland HD; Bhatia A
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of cefepime pharmacokinetics in neonatal foals and adult dogs.
    Gardner SY; Papich MG
    J Vet Pharmacol Ther; 2001 Jun; 24(3):187-92. PubMed ID: 11442796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of pharmacokinetic interaction between cefepime and amikacin in humans.
    Barbhaiya RH; Knupp CA; Pfeffer M; Pittman KA
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1382-6. PubMed ID: 1510431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The importance of pharmacokinetic consultation of cefepime treatment for Pseudomonas aeruginosa bacteremia: a case report of severe thermal burn injury.
    Aoki Y; Urakami T; Magarifuchi H; Nagasawa Z; Nagata M; Fukuoka M
    J Infect Chemother; 2011 Jun; 17(3):407-11. PubMed ID: 20922450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subcutaneous administration of cefepime.
    Walker P; Neuhauser MN; Tam VH; Willey JS; Palmer JL; Bruera E; Prince RA
    J Pain Symptom Manage; 2005 Aug; 30(2):170-4. PubMed ID: 16125032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients.
    Joynt GM; Lipman J; Gomersall CD; Young RJ; Wong EL; Gin T
    J Antimicrob Chemother; 2001 Apr; 47(4):421-9. PubMed ID: 11266414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review of the pharmacokinetics of cefepime in children.
    Blumer JL; Reed MD; Knupp C
    Pediatr Infect Dis J; 2001 Mar; 20(3):337-42. PubMed ID: 11303847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration.
    Allaouchiche B; Breilh D; Jaumain H; Gaillard B; Renard S; Saux MC
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2424-7. PubMed ID: 9371344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients.
    Cheatham SC; Shea KM; Healy DP; Humphrey ML; Fleming MR; Wack MF; Smith DW; Sowinski KM; Kays MB
    Int J Antimicrob Agents; 2011 Jan; 37(1):46-50. PubMed ID: 21074370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study.
    Huwyler T; Lenggenhager L; Abbas M; Ing Lorenzini K; Hughes S; Huttner B; Karmime A; Uçkay I; von Dach E; Lescuyer P; Harbarth S; Huttner A
    Clin Microbiol Infect; 2017 Jul; 23(7):454-459. PubMed ID: 28111294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.